Split History
ETFs Holding CTXR »    CTXR Historical Stock Prices »



Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. It develops and commercializes critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Its products include LYMPHIR, Mino-Lok, Halo-Lido, NoveCite and Mino-Wrap. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. According to our CTXR split history records, Citius Pharmaceuticals has had 1 split.
CTXR split history picture
Citius Pharmaceuticals (CTXR) has 1 split in our CTXR split history database. The split for CTXR took place on November 26, 2024. This was a 1 for 25 reverse split, meaning for each 25 shares of CTXR owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 40 share position following the split.

When a company such as Citius Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the CTXR split history from start to finish, an original position size of 1000 shares would have turned into 40 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Citius Pharmaceuticals shares, starting with a $10,000 purchase of CTXR, presented on a split-history-adjusted basis factoring in the complete CTXR split history. CTXR split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 06/13/2017
End date: 06/20/2025
Start price/share: $165.00
End price/share: $1.08
Dividends collected/share: $0.00
Total return: -99.35%
Average Annual Total Return: -46.56%
Starting investment: $10,000.00
Ending investment: $65.50
Years: 8.02
Date Ratio
11/26/20241 for 25
CTXR is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

CUR Split History
CVM Split History
CWBR Split History
CXM Split History
CYCC Split History
CYH Split History
CYTK Split History
CYTR Split History
CYTX Split History
DARA Split History

Also explore: CTXR shares outstanding history

Email EnvelopeFree CTXR Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Cellectar Biosciences, Inc. (CLRB)
Super League Enterprise, Inc. (SLE)
TruGolf Holdings, Inc. (TRUG)
Brenmiller Energy Ltd. (BNRG)
Unicycive Therapeutics, Inc. (UNCY)
RAPT Therapeutics, Inc. (RAPT)
Sensei Biotherapeutics, Inc. (SNSE)
FibroGen, Inc. (FGEN)
Jeffs' Brands Ltd (JFBR)
SMX Public Limited Company (SMX)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

CTXR Insider Buying

CTXR Split History | www.SplitHistory.com | Copyright © 2013 - 2025, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.